In the United States in 2016, prescription opioids accounted for 40% of the 42 249 opioid-related overdose deaths.1 Although the number of opioid prescriptions has been declining over the past several years, prescribing remains elevated relative to 1999 levels.2 This study examines opioid prescribing at the national and county levels in 2015 and 2017.
Methods |
Data come from IQVIA’s Xponent database, which contains prescriptions dispensed from approximately 50 400 retail pharmacies, representing 90% of prescriptions in the United States. Opioid prescribing at the national and county levels were analyzed for 2015 and 2017. Measures included overall opioid prescribing rates, high-dose prescribing rates, morphine milligram equivalent (MME) per capita, average daily MME per prescription, and average and median prescription duration. The MME was calculated using published ratios.3 To compute MME per capita, total MME was divided by population estimates. Prescribing rates were calculated per 100 persons. Annual population estimates were obtained from the US Census Bureau and included individuals of all ages. High-dose prescriptions were defined as those resulting in 90 or more MME per day. Cough and cold formulations containing opioids and buprenorphine products typically used for opioid-use disorder were excluded. County-level opioid prescribing was examined by quartile. All analyses were performed in Stata, version 14.2 (StataCorp). The Centers for Disease Control and Prevention determined this study to be exempt from human-subject regulations and institutional review board approval.
Results |
From 2015 to 2017, the amount of opioids prescribed in the United States decreased 20.1%, from 641.4 to 512.6 MME per capita; opioid prescribing rates decreased 16.9%, from 70.7 to 58.7 per 100 persons; high-dose prescribing rates decreased 25.3%, from 6.7 to 5.0 per 100 persons; and the average daily MME per prescription decreased 6.0%, from 48.1 to 45.2 MME (Table). Meanwhile, average and median duration of opioid prescriptions increased by 3.4% (17.7 to 18.3 days) and 33.3% (15.0 to 20.0 days), respectively.
Table.
National- and County-Level Opioid Prescribing in the United States, 2015 and 2017
| Prescribing Measure | National Level |
County Level |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2015 | 2017 | Change, % | Opioid Prescribing in 2017 by Quartilea |
Counties With Changes, 2015 to 2017, No. (%)b |
||||||
| Lowest | Second | Third | Highest | Decrease | Stable | Increase | ||||
| MME per capita | 641.4 | 512.6 | −20.1 | 182.8 | 437.3 | 641.1 | 1061.0 | 2204 (74.7) | 498 (16.9) | 247 (8.4) |
| Overall prescribing ratec | 70.7 | 58.7 | −16.9 | 25.1 | 55.1 | 76.0 | 115.8 | 2251 (76.3) | 499 (16.9) | 199 (6.8) |
| High-dose prescribing ratec,d | 6.7 | 5.0 | −25.3 | 1.5 | 3.9 | 6.0 | 10.6 | 2259 (76.6) | 380 (12.9) | 310 (10.5) |
| Average daily MME per prescription | 48.1 | 45.2 | −6.0 | 34.3 | 40.5 | 45.1 | 53.8 | 583 (19.8) | 2235 (75.8) | 131 (4.4) |
| Average duration of prescriptions, d | 17.7 | 18.3 | 3.4 | 15.8 | 18.0 | 19.7 | 21.9 | 50 (1.7) | 2636 (89.4) | 263 (8.9) |
| Median duration of prescriptions, d | 15.0 | 20.0 | 33.3 | 12.2 | 17.0 | 25.5 | 30.0 | 193 (6.5) | 1634 (55.4) | 1122 (38.1) |
Abbreviation: MME, morphine milligram equivalent.
Quartiles were created using MME per capita to characterize the distribution of opioids prescribed.
Among the 2949 counties with available data in 2015 and 2017, changes of ≥10% were considered to represent an increase or decrease, whereas changes <10% were considered stable.
Prescribing rates are presented per 100 persons.
High-dose prescribing rate includes opioid prescriptions with daily dosage ≥90 MME.
In 2017, the amount of opioids prescribed per capita varied substantially at the county level (Figure and Supplement). The average amount of opioids prescribed in the highest quartile (1061.0 MME per capita) was 5.8 times the amount in the lowest quartile (182.8 MME per capita) (Table). Substantial variation between the highest and lowest prescribing counties was also observed for overall prescribing rates (4.6 times higher) and high-dose prescribing rates (7.1 times higher). From 2015 to 2017, the majority of counties experienced a reduction in the amount of opioids prescribed (2204 [74.7%]), overall prescribing rates (2251 [76.3%]), and high-dose prescribing rates (2259 [76.6%]).
Figure.
Opioid Prescribing in the United States by County in 2015 and 2017. Although the amount of morphine milligram equivalent (MME) of opioids prescribed per capita varied substantially at the county level in 2017 (A), the amount of opioids prescribed in the United States between 2015 and 2017 decreased overall (B). Image created and published with permission by Randall Young, MA, of the Centers for Disease Control and Prevention.
Discussion |
The reduction in opioid prescribing that began in 2012 has accelerated in the United States. The amount of opioids prescribed decreased an average of 10.0% annually with reductions in 74.7% of counties from 2015 to 2017, compared with 3.6% annually with reductions in 49.6% of counties from 2010 to 2015.2 However, opioids continued to be prescribed at 512.6 MME per capita in 2017, nearly triple the amount prescribed in 1999.2
The duration of opioid prescriptions continues to increase nationally, likely because of greater decreases in shorter-term opioid prescriptions (<30 days) than in longer-term prescriptions.2 Average duration remained stable in 89.4% of counties from 2015 to 2017, in contrast with 2010 to 2015 in which 73.5% of counties experienced an increase.2
Recent reductions could be related to policies and strategies aimed at reducing inappropriate prescribing, increased awareness of the risks associated with opioids, and release of the CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016.4–6 Despite reductions in prescribing, opioid overdose rates continue to increase and are driven largely by illicitly manufactured fentayl.1 The opioid overdose epidemic is a complex crisis requiring coordination across multiple sectors, including public health, health care, and public safety.
Limitations of this study include the inability to determine the appropriateness of opioid prescriptions, lack of data on prescriptions dispensed outside of retail pharmacies (ie, mail-order, prescriber-dispensed, and hospital- or clinic-based pharmacies), and the reliance on where the prescription was dispensed, rather than where it was prescribed or used. Nonetheless, this study provides national- and county-level information on opioid prescribing to help inform efforts in improving opioid prescribing in the United States.
Supplementary Material
Acknowledgments
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Footnotes
Conflict of Interest Disclosures: None reported.
Contributor Information
Gery P. Guy, Jr, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia.
Kun Zhang, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia.
Lyna Z. Schieber, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia.
Randall Young, Division of Toxicology and Human Health Sciences, Agency for Toxic Substances and Disease Registry, Centers for Disease Control and Prevention, Atlanta, Georgia.
Deborah Dowell, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia.
References
- 1.Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016. MMWR Morb Mortal Wkly Rep 2018;67(12):349–358. doi: 10.15585/mmwr.mm6712a1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Guy GP Jr, Zhang K, Bohm MK, et al. Vital signs: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017;66(26): 697–704. doi: 10.15585/mmwr.mm6626a4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.CDC compilation of benzodiazepines, muscle relaxants, stimulants, zolpidem, and opioid analgesics with oral morphine milligram equivalent conversion factors. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control https://www.cdc.gov/drugoverdose/resources/data.html. Updated October 19, 2018. Accessed January 4, 2019. [Google Scholar]
- 4.Lin LA, Bohnert ASB, Kerns RD, Clay MA, Ganoczy D, Ilgen MA. Impact of the Opioid Safety Initiative on opioid-related prescribing in veterans. Pain 2017; 158(5):833–839. doi: 10.1097/j.pain.0000000000000837 [DOI] [PubMed] [Google Scholar]
- 5.Hwang CS, Turner LW, Kruszewski SP, Kolodny A, Alexander GC. Prescription drug abuse: a national survey of primary care physicians. JAMA Intern Med 2015;175(2):302–304. doi: 10.1001/jamainternmed.2014.6520 [DOI] [PubMed] [Google Scholar]
- 6.Bohnert ASB, Guy GP Jr, Losby JL. Opioid prescribing in the United States before and after the Centers for Disease Control and Prevention’s 2016 opioid guideline. Ann Intern Med 2018;169(6):367–375. doi: 10.7326/M18-1243 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.